Johnson & Johnson stock declined as a judge rejected its $10 billion settlement offer for cancer lawsuits related to its talc-based products. The company plans to continue fighting the claims in civil court. J&J stopped selling talc baby powder in the U.S. and shifted liabilities to a subsidiary.